ZOMETA AND PAGET'S DISEASE
Paget's disease is a metabolic bone disease that involves bone destruction and regrowth
which results in deformity.
Current treatments are biphosphonates (etidronate
(Didronel), alendronate (Fosamax), pamidronate
(Aredia), tiludronate (Skelid), and risedronate (Actonel))
and calcitonin (Miacalcin, Calcimar) and nonsteroidal
anti-inflammatory medications (NSAIDS; for pain).
Currently, Novartis' Zometa is under review by the U.S.
FDA as a treatment for Paget's disease. Zometa has
been approved for that use in some other countries.
Zoledronic acid is a bisphosponate administered as a
single intravenous infusion.

In two identical, randomized, double-blind, actively
controlled studies of 6 months' duration, researchers
compared one 15-minute infusion of 5 mg of zoledronic
acid with 60 days of oral risedronate (30 mg per day).
Researchers found that 96% of patients receiving
zoledronic acid had a therapeutic response, as
compared with 74.3 percent of patients receiving
risedronate. And, alkaline phosphatase levels
normalized in 88.6 percent of patients in the zoledronic
acid group and 57.9 percent of patients in the
risedronate group.

Reference:

Ian R. Reid. Comparison of a Single Infusion of
Zoledronic Acid with Risedronate for Paget's Disease.
The New England Journal of Medicine Volume
353:898-908 September 1, 2005 Number 9
Novartis drug aids bones in Paget's disease-study,
Reuters, Aug 31, 2005.
Zoledronic Acid Improves Femoral Head Sphericity in a
Rat Model of Perthes Disease. RedNova online
publication, August 7, 2005.
THIS WEBSITE TALKS ABOUT THE SIDE EFFECTS AND THE POTENTIAL HEALTH BENEFITS OF HERBS, SUPPLEMENTS,